All 13 patients with dizziness (100%) and 9 of 16 with hypotension (56%) were relieved of adverse symptoms or signs
84 ± 1
Aug 7, 2019 · Clinical guidelines suggest that for patients with heart failure and concurrent chronic obstructive pulmonary disease (COPD), metoprolol/bisoprolol/nebivolol should be preferred over carvedilol
Journal of Cardiology Volume 75, Issue 2, February 2020, Pages 140-147 Original article Effects of carvedilol vs bisoprolol on inflammation and oxidative stress
6, P = 0
Beta-blockers are the mainstay of CHF
1016/S0954-6111 (11)70010-5 Chronic obstructive pulmonary disease (COPD) frequently coexists in patients with chronic heart failure (CHF) and is a key factor for
Four β-blockers are indicated in this setting, carvedilol, bisoprolol, metoprolol, and nebivolol, which differ in their peripheral vascular effects and selectivity for adrenergic
Furthermore, to assess the dose effect, we analyzed the risk of outcomes according to the dose groups as per heart failure guidelines [18, 19] during the 90-day exposure period
This study compared effects of bisoprolol and carvedilol in patients with both conditions
But we now have longer-acting metoprolol succinate
Since they don't usually affect the lungs, one of these medications may be a better choice if you have asthma
The date of bisoprolol or carvedilol prescription was set as the index date (Supplementary data, Figure S1)
This is particularly evident in elderly patients, which may be due to a fear of side-effects or
To be eligible for this study, patients had to (1) attend the heart failure outpatients’ clinic of any of the participating hospitals, (2) provide written informed consent for inclusion into the heart failure registry, (3) have a history of systolic heart failure, and (4) be treated with either carvedilol or metoprolol succinate in Treatment with carvedilol is an established primary therapy for patients with heart failure (HF)
1 In this, the largest and longest-running Beta-blocker treatment in heart failure
Bisoprolol is highly
Three β-adrenergic blockers—bisoprolol, carvedilol, and metoprolol succinate—have been shown to reduce mortality and morbidity in patients with HF resulting from LV systolic dysfunction (LVSD)